Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-30

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The authors hypothesize that there is a correlation between the percentage of CD4+ T cells expressing CD32a and/or X and the quantity of DNA found in peripheral blood mononuclear cells in patients infected with HIV-1. Also, that there is a correlation between expression of CD32a and/or X and proviral load.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

NCT00002359

HIV Infections

COMPLETED PHASE3

Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers

NCT00027482

Healthy HIV Infection

COMPLETED

Evaluation of HIV-Negative Patients With Low CD4+ T Lymphocyte Counts

NCT00001319

CD4 Lymphocytopenia Idiopathic CD4 Positive T Lymphocytopenia

COMPLETED

Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy

NCT05433987

HIV-1-infection

COMPLETED

Cytomegalovirus Infection in Patients With HIV-1 Infection

NCT04067869

Cytomegalovirus Infections HIV-1-infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1-infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-A infected patients

Bioclinical evaluation

Intervention Type OTHER

50-100ml blood extracted for flow cytometry and qPCR

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bioclinical evaluation

50-100ml blood extracted for flow cytometry and qPCR

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient infected with aviremic HIV-1 (\<20 copies of HIV-1 RNA/ml plasma) undergoing antiretroviral treatment for at least 2 years
* Patient has known duration of infection and treatment
* Patient has known pretherapeutic CD4+ T cell count and viremia
* Patient has known CD4+ T cell count, residual viremia and CD4/CD8 ratio for previous 2 years
* Patient weighs at least 56kg
* The patient is not opposed to their inclusion in the study
* The patient must be a member or beneficiary of a health insurance plan
* Patient at least 18 years old

Exclusion Criteria

* Patient has an acute infection
* The subject has already been included in the study or is in a period of exclusion determined by a previous study
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* Patient is pregnant, parturient or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No